• Publications
  • Influence
The disposition of carboplatin in the beagle dog
SummaryCarboplatin was administered i.v. to four groups of three male beagle dogs at doses of 3, 6, 12, and 24 mg/kg (60–580 mg/m2). Plasma samples were obtained at appropriate times and protein-freeExpand
Validated HPLC procedures for the analysis of BMY-28090 in human plasma and urine
SummaryThe compound BMY-28090 (elsamicin A) is a new fermentation product with antitumor properties, which has the same aglycone as chartreusin but contains two novel sugars. To define theExpand
In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin
SummaryRadiochemically pure 14C-labeled carboplatin, cis-diammine [1,1-cyclobutane (1-14C) dicarboxylato (2-)-0,0'] platinum (II), was added to fresh human, dog and rat plasma, at concentrationsExpand
Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine.
A new tetravalent meningococcal polysaccharide vaccine containing groups A, C, W 135, and Y was administered to 40 healthy adults. The vaccine was well tolerated and bactericidal assay showed meanExpand
The disposition of carboplatin in ovarian cancer patients
SummaryCarboplatin was given as a 30-min infusion to 11 ovarian cancer patients at doses of 170–500 mg/m2. The ages, weights, and creatinine clearances (Clcr) ranged from 44 to 75 years, from 44 toExpand